贵州百灵(002424.SZ)：糖宁通络片临床试验申请获批准

Group 1 - The core point of the article is that Guizhou Bailing (002424.SZ) announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial of Tangning Tongluo tablets, which are intended for the treatment of type 2 diabetes [1] Group 2 - The approval allows Bailing Yuxiu to conduct clinical trials for Tangning Tongluo tablets, marking a significant step in the company's development of diabetes treatment options [1]